By Fineline Cube 
Japan-based Eisai Co., Ltd. (TYO: 4523) announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for its Dayvigo (lemborexant). This approval introduces a new treatment option for patients suffering from insomnia, further expanding the therapeutic landscape for sleep disorders.
Lemborexant Mechanism and Benefits
Lemborexant, a dual orexin receptor antagonist, works by competitively binding to two types of orexin receptors (OX1R and OX2R). This action inhibits orexin neurotransmission and regulates the sleep-wake rhythm. Clinical data indicate that lemborexant shortens the time to fall asleep, reduces nighttime awakenings, and prolongs total sleep time. Unlike traditional GABA-A receptor agonists, lemborexant does not suppress the REM sleep phase but instead helps to positively regulate the sleep structure, making it closer to physiological sleep by simultaneously prolonging non-REM and REM sleep phases.-Fineline Info & Tech